Search results
Produce a new standalone guideline on uncontrolled asthma that includes guidance on pharmacological management (specifically biologics), assessment, phenotyping, high-risk patients, biomarkers and monitoring (replacing the existing sections 7 and 10).
BTS/SIGN/NICE joint Guideline for the Diagnosis, Monitoring and Management of Chronic Asthma. The draft guideline, evidence reviews and information on the consultation on the guideline is here. The full scope of the guideline is available here. The Consultation period is now closed. - July 2024.
Guidelines Network (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using evidence-based methodology explicitly.
guideline published in September 2016 (SIGN 153) and July 2019 (SIGN 158). The guideline development process for SIGN 153 involved 65 healthcare professionals, a representative from Asthma UK, and one patient representative.
This is a new collaborative guideline produced by BTS, NICE and SIGN. It updates NICE guideline 80 (published November 2017) and parts of BTS/SIGN guideline (SIGN 158, published July 2019). Who is it for? • GPs and practice nurses • Healthcare professionals in secondary care and tertiary asthma services • Commissioners and providers
Published by: British Thoracic Society/SIGN. The final scope for the NICE/BTS/SIGN joint Guideline for the Diagnosis, Monitoring and Management of Chronic Asthma is available here. Access the Guideline.
These include guidance on inhaler devices, the management of acute asthma attacks in both adults and children, the management of difficult asthma, guidance on asthma in adolescents, in pregnant women and on occupational factors.
